Ciprofloxacin hydrochloride hydrate

Chemical properties

Pale yellow, crystalline, slightly hygroscopic powder.

The Uses of Ciprofloxacin hydrochloride hydrate

Fluoroquinolone antibacterial.

The Uses of Ciprofloxacin hydrochloride hydrate

Ciprofloxacin hydrochloride has been suggested as a treatment for a wide range of infections caused by susceptible organisms including infections of urinary, respiratory, and gastrointestinal tracts, gonorrhoea and septicaemia. Nalidixic acid analogue.

What are the applications of Application

Ciprofloxacin Hydrochloride Monohydrate is A second generation fluoroquinolone antibiotic

Definition

ChEBI: The monohydrate form of ciprofloxacin monohydrochloride.

What are the applications of Application

Ciprofloxacin hydrochloride hydrate is a broad-spectrum antibiotic that inhibits bacterial DNA gyrase and blocks DNA synthesis and replication, resulting in bacterial death. It has strong antibacterial activity against Escherichia coli, Klebsiella and other Enterobacteriaceae; the antibacterial activity against Pseudomonas aeruginosa, Staphylococcus aureus and Streptococcus pneumoniae is better than norfloxacin and pefloxacin.

brand name

Ciloxan (Alcon); Cipro (Bayer); Proquin (Esprit).

General Description

Ciprofloxacin HCl is a fluoroquinolone antibiotic agent, which shows a broad spectrum of antibacterial activity against gram positive and gram negative bacteria.

in vitro

Ciprofloxacin (hydrochloride monohydrate) is a fluoroquinolone antibiotic, exhibiting potent antibacterial activity. Ciprofloxacin (hydrochloride monohydrate) (CIP) shows potent activity against Y. pestis with MIC 90 of 0.03 μg/mL.

in vivo

Ciprofloxacin (hydrochloride monohydrate) (1 mg/L) induces glutathione-S-transferase (GST) activity, in contrast with inhibited GST and Catalase (CAT) of larvae exposed to enrofloxacin. Ciprofloxacin (hydrochloride monohydrate) (≥10 μg/L) is ecotoxic for development, growth, detoxifying, and oxidative stress enzymes in anuran amphibian larvae. In a murine model of pneumonic plague, Ciprofloxacin (hydrochloride monohydrate) (30 mg/kg, i.p.) results in a drug exposure which is similar to the drug exposure observed in human following a 500 mg dose of oral Ciprofloxacin (hydrochloride monohydrate). Intraperitoneal Ciprofloxacin (hydrochloride monohydrate) reduces the lung bacterial load compare to controls treated with intraperitoneal PBS.